Clinical implications of novel mutations in epigenetic modifiers in AML.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Hematology/Oncology Clinics of North America

• Publication date

  2011-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.hoc.2011.09.013PMID 22093580
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IDH mutations in acute myeloid leukemia.

  2012cited by this paper
• Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production

  2012cited by this paper
• Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML–BFM and DCOG study groups

  2011cited by this paper
• Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia

  2011cited by this paper
• MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.

  2011cited by this paper
• Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain.

  2011cited by this paper
• TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.

  2011cited by this paper
• Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

  2011cited by this paper
• Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

  2011cited by this paper
• TET2 mutations in secondary acute myeloid leukemias: a French retrospective study

  2011cited by this paper
• Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes

  2011cited by this paper
• PHF6 mutations in adult acute myeloid leukemia

  2011cited by this paper
• Leukemic mutations in the methylation‐associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children's Oncology Group

  2011cited by this paper
• Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors

  2011cited by this paper
• The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.

  2011cited by this paper
• Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.

  2011cited by this paper
• TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

  2011cited by this paper
• Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

  2011cited by this paper
• IDH1 and IDH2 mutations in pediatric acute leukemia

  2011cited by this paper
• TET2 mutations in childhood leukemia

  2011cited by this paper
• DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms

  2011cited by this paper
• Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers.

  2011cited by this paper
• The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration

  2010cited by this paper
• Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.

  2010cited by this paper
• Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

  2010cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

  2010cited by this paper
• Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.

  2010cited by this paper
• Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.

  2010cited by this paper
• IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

  2010cited by this paper
• Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951.

  2010cited by this paper
• A single-tube, sensitive multiplex method for screening of isocitrate dehydrogenase 1 (IDH1) mutations.

  2010cited by this paper
• Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

  2010cited by this paper
• Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.

  2010cited by this paper
• Array-based genomic resequencing of human leukemia

  2010cited by this paper
• Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

  2010cited by this paper
• IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

  2010cited by this paper
• The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

  2010cited by this paper
• IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

  2010cited by this paper
• DNMT3A mutations in acute myeloid leukemia.

  2010cited by this paper
• The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status.

  2010cited by this paper
• High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial

  2010cited by this paper
• TET2 Mutations In Acute Myeloid Leukemia (AML): Results on 783 Patients Treated within the AML HD98A Study of the AML Study Group (AMLSG)

  2010cited by this paper
• IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

  2010cited by this paper
• AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.

  2009cited by this paper
• Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1

  2009cited by this paper
• Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

  2009cited by this paper
• Recurring mutations found by sequencing an acute myeloid leukemia genome.

  2009cited by this paper
• Anthracycline dose intensification in acute myeloid leukemia.

  2009cited by this paper
• TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

  2009cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2009cited by this paper
• Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).

  2009cited by this paper
• Review Articles (434 articles)

  2008cited by this paper
• Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

  2008cited by this paper
• Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

  2007cited by this paper
• Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse.

  2002cited by this paper
• Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm.

  2002cited by this paper
• Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia

  2000cited by this paper
• Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.

  1998cited by this paper

• Advances in the role of the IGF signaling system in myelodysplastic syndromes and acute myeloid leukemia

  2025cites this paper
• Research Progress in the Relationship and Role of IDH1/2 Gene Mutation and Acute My-eloid Leukemia

  2023cites this paper
• Comparison of DNA Sequencing and Multispecific Monoclonal Antibody (Msmab-1) based Immunohistochemical Detection of IDH1/2 Mutation in Acute Myeloid Leukemia Cases.

  2023cites this paper
• O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy

  2022cites this paper
• A concise review on the molecular genetics of acute myeloid leukemia.

  2021cites this paper
• Gene Expression Analysis of Pediatric Acute Myeloid Leukemia Identified a Hyperactive ASXL1/BAP1 Axis Linked with Poor Prognosis and over Expressed Epigenetic Modifiers

  2021cites this paper
• Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation

  2020cites this paper
• Murine Models of Myelofibrosis

  2020cites this paper
• IDH1 and IDH2 Mutations as Novel Therapeutic Targets in Acute Myeloid Leukemia (AML): Current Perspectives

  2020cites this paper
• Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection

  2019cites this paper
• Translation of cancer immunotherapy from the bench to the bedside.

  2019cites this paper
• Rescue of TCA Cycle Dysfunction for Cancer Therapy

  2019cites this paper
• Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy

  2019cites this paper
• Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation.

  2018cites this paper
• A novel ASXL1–OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies

  2018cites this paper
• Gene mutation patterns of Chinese acute myeloid leukemia patients by targeted next-generation sequencing and bioinformatic analysis.

  2018cites this paper
• Recent advances in the understanding and treatment of acute myeloid leukemia

  2018cites this paper
• Next generation sequencing to identify multiple clinically relevant genetic lesions for the diagnosis of acute myeloid leukaemia

  2018influential citation
• Imaging and Metabolism

  2017cites this paper
• JNK1 as a signaling node in VDR-BRAF induction of cell death in AML.

  2017cites this paper
• DNA and Histone Methylation in Hematopoietic Malignancy

  2017cites this paper
• [Aberrant DNA methylation and its targeted therapy in acute myeloid leukemia].

  2016cites this paper
• IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

  2016cites this paper
• Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study

  2016cites this paper
• Review: Aberrant EVI1 expression in acute myeloid leukaemia

  2016cites this paper
• Nucleosome Density ChIP-Seq Identifies Distinct Chromatin Modification Signatures Associated with MNase Accessibility.

  2016cites this paper
• AWARD NUMBER: W81XWH-12-1-0041 TITLE: Understanding and Targeting Epigenetic Alterations in Acquired Bone Marrow Failure

  2015cites this paper
• D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH

  2015cites this paper
• Epigenetic deregulation in myeloid malignancies.

  2015cites this paper
• Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.

  2015cites this paper
• Emerging Therapies in Cytogenetically Normal Acute Myeloid Leukemia

  2015cites this paper
• New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.

  2015cites this paper
• Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia

  2015cites this paper
• Structure, regulation, and function of TET family proteins

  2015cites this paper
• Genomic tools in acute myeloid leukemia: From the bench to the bedside

  2014cites this paper
• C-terminal-truncating ASXL1 mutations induce MDS via inhibition of PRC2

  2014cites this paper
• Is Targeted Therapy Feasible in Acute Myelogenous Leukemia?

  2014cites this paper
• Markers for Diagnosis, Prognosis, and Therapy of Acute Myeloid Leukemia

  2014cites this paper
• Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia

  2014influential citation
• Recent Discoveries in Molecular Characterization of Acute Myeloid Leukemia

  2014cites this paper
• Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.

  2013cites this paper
• (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible

  2013cites this paper
• Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.

  2013cites this paper
• Mutations in epigenetic modi fi ers in the pathogenesis and therapy of acute myeloid leukemia

  2013cites this paper
• What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.

  2013cites this paper
• acute myeloid leukemia Mutations in epigenetic modifiers in the pathogenesis and therapy of

  2013cites this paper
• Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies.

  2013cites this paper